##plugins.themes.academic_pro.article.sidebar##

Download
pdf
Statistic
Read Counter : 61 Download : 53

##plugins.themes.academic_pro.article.main##

Abstract

Environmental pollution, repeated artificial termination of pregnancy, and improper use of medications create conditions for the development of breast cancer (BC). According to the World Health Organization, “... throughout the world, breast cancer ranks first among malignant neoplasms in women and is characterized by high mortality. According to statistics, about 1.67 million new cases are diagnosed annually in the world, more than 571 thousand women die from breast cancer...” 1According to the literature, “...triple-negative breast cancer (TNBC) accounts for about 8-20% of all breast tumors, more often found in women before menopause, with early menarche, with the first pregnancy at an earlier age, with a short period of breastfeeding and increased body mass index ..." 2 . Frequent recurrence of the disease as a result of inadequate diagnosis and treatment, as well as the search for methods of its prevention are one of the pressing problems facing physicians.

Keywords

women breast cancer problems period

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite
Atakhanova N. E, Almuradova D. M, & Ziyaev Sh. V. (2023). Modern View on the Problem of Triple Negative Breast Cancer. Texas Journal of Medical Science, 26, 21–25. https://doi.org/10.62480/tjms.2023.vol26.pp21-25
Crossref
Scopus
Google Scholar
Europe PMC

References

  1. Amos KD, Adamo B, Anders CK. Triple-negative breast cancer: an update on neoadjuvant clinical trials. Int J Breast Cancer. 2012;385978.
  2. Hu R. et al. Androgen receptor expression and breast cancer survival in postmenopausal women // Clin. Cancer. Res. – 2011 Apr. – Vol. 17, N7. – P. 1867–1874.
  3. McGhan L.J. et al. Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype // Ann.Surg. Oncol. – 2014 Feb. – Vol. 21, N2. – P. 361–367.
  4. Banerji S., Cibulskis K., Rangel-Escareno C., Brown K. K., Carter S. L., Frederick A. M. et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012; 486: Р. 405–9.
  5. Barbie T. U., Alexe G., Aref A. R., Li S., Zhu Z., Zhang X. et al. Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. J Clin Invest 2014; 124: Р. 5411–23.
  6. Baselga J., Gomez P., Greil R., Braga S., Climent M. A., Wardley A. M. et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol 2013; 31:2586–92.
  7. Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a populationbased study from the California Cancer Registry. Cancer. 2007; 109: Р. 1721-1728.
  8. Bethesda, MD, National Cancer Institute. Robertson, L., Hanson, H., Seal, S., Warren-Perry, M., Hughes, D., Howell, I…& TNT Trial TMG; BCSC (UK). (2012). BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. British Journal of Cancer, 106(6), 1234-1238.
  9. Bidard FC, Conforti R, Boulet T, Michiels S, Delaloge S, Andre F. Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 'triple-negative' breast cancers. Ann Oncol. 2012;18(7): 1285–6.
  10. Atakhanova N.E, Almuradova D.M, Gaziev L.T, Sadullaeva N.I, Erkinova Ch.O. Androgen receptor values for prediction of survival of patients with three times negative breast cancer. World Bulletin of Public Health, 22, 140-142, 2023.
  11. Almuradova D.M, Odilova Sh.Sh, Ubaydullaev I.A, Sharobiddinov B.B. Islamov S.B. A Modern Approach to Diagnosis and Treatment of Breast Cancer Releases. Central Asian Journal of Medical and Natural Science, 2(5), 294-298, 2021.
  12. Khakimova G.G, Khakimov G.A, Khakimova Sh.G, Кhakimov A.T, Almuradovа D.M. Changes In Tumor Infiltrating Lymphocytes Of Peripheral Blood And Tissue During Chemotherapy In Patients With Gastric Cancer. The American Journal of Medical Sciences and Pharmaceutical Research. Т 3 (03), 20-31, 2020.
  13. MD Juraev, NE Atakhanova, DM Almuradova, LT Gaziev. Androgen receptor values for prediction of survival of patients with three times negative breast cancer. EPRA International Journal of Research and Development (IJRD) 8 (6), 104-106, 2023
  14. M.N Tilyashaikhov, L.T Gaziev, A. Almuradov, D.M Almuradova. A Modern Approach to Diagnostics, Prediction and Course of Renal Cell Cancer. Annals of the Romanian Society for Cell Biology, 4429–4451, 2021.
  15. Атаханова Н.Э, Алмурадова Д.М. Влияние экспрессии андрогеновых рецепторов на прогноз трижды негативного рака молочной железы. Клиническая и экспериментальная онкология. Т 10 (2), 112-115, 2022.
  16. Atakhanova N.E, Almuradova D.M, Gaziev L.T, Ziyayev Sh.V. Results of Drug Treatment of patients with metastasis of triple times negative breast cancer. EPRA International Journal of Research and Development (IJRD) 9 (6), 125-128, 2023.
  17. Atakhanova N.E, Almuradova D.M, Ziyayev Sh.V, Хамидов Х, Юсупов А. Значения андрогенных рецепторов для прогнозирования выживаемости больных трижды негативным раком молочной железы. International Bulletin of Medical Sciences and Clinical Research. 3 (6), 5-8 , 2023.
  18. D.M Almuradova, D.I Mukumova, X.Kh Turaeva, Karlibaev A.O. Modern endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer. Образования и наука в ХХI веке. 24 (2), 773-780, 2022.
  19. Н.Э Атаханова, Д.М Алмурадова, И.А. Дудина. Молекулярно-биологические характеристики трижды негативного рака молочной железы. Российский биотерапевтический журнал. 17 (1), 23-27, 2018